



Improving the Stability of Protein–Protein Interaction Assay FlimPIA Using a Thermostabilized Firefly Luciferase

Yuki Ohmuro-Matsuyama^{1,2,3}, Keiko Gomi⁴, Takuya Shimoda², Hideki Yamaji² and Hiroshi Ueda^{1*}

¹Laboratory of Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan, ²Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Kobe, Japan, ³Technology Research Laboratory, Shimadzu Corporation, Kyoto, Japan, ⁴Kikkoman Co., Ltd., Noda, Japan

OPEN ACCESS

Edited by:

Vadim R. Viviani,
Federal University of São Carlos, Brazil

Reviewed by:

Shiburaj Sugathan,
University of Kerala, India
Wen-Chao Yang,
Central China Normal University,
China

*Correspondence:

Hiroshi Ueda
ueda@res.titech.ac.jp

Specialty section:

This article was submitted to
Biomaterials,
a section of the journal
Frontiers in Bioengineering and
Biotechnology

Received: 16 September 2021

Accepted: 27 October 2021

Published: 11 November 2021

Citation:


Ohmuro-Matsuyama Y, Gomi K, Shimoda T, Yamaji H and Ueda H (2021) Improving the Stability of Protein–Protein Interaction Assay FlimPIA Using a Thermostabilized Firefly Luciferase. *Front. Bioeng. Biotechnol.* 9:778120. doi: 10.3389/fbioe.2021.778120

The protein–protein interaction assay is a key technology in various fields, being applicable in drug screening as well as in diagnosis and inspection, wherein the stability of assays is important. In a previous study, we developed a unique protein–protein interaction assay “FlimPIA” based on the functional complementation of mutant firefly luciferases (Fluc). The catalytic step of Fluc was divided into two half steps: D-luciferin was adenylated in the first step, while adenylated luciferin was oxidized in the second step. We constructed two mutants of Fluc from *Photinus pyralis* (Ppy); one mutant named Donor is defective in the second half reaction, while the other mutant named Acceptor exhibited low activity in the first half reaction. To date, Ppy has been used in the system; however, its thermostability is low. In this study, to improve the stability of the system, we applied Fluc from thermostabilized *Luciola lateralis* to FlimPIA. We screened suitable mutants as probes for FlimPIA and obtained Acceptor and Donor candidates. We detected the interaction of FKBP12-FRB with FlimPIA using these candidates. Furthermore, after the incubation of the probes at 37°C for 1 h, the luminescence signal of the new system was 2.4-fold higher than that of the previous system, showing significant improvement in the stability of the assay.

Keywords: protein-protein interaction (PPI), firefly luciferase (Fluc), bioluminescence, adenylation, oxidative reaction, thermostability, assay stability

1 INTRODUCTION

The protein–protein interaction (PPI) assay is a key technology, not only in basic biology but also for practical purposes in drug screening (Gul and Hadian, 2014; Xu et al., 2016; Ashkenazi et al., 2017), diagnosis (Yuan et al., 2017; Atan et al., 2018), and food inspection (Rasooly, 2001; Katam et al., 2016). We previously developed a PPI assay based on the two divided catalytic reactions of firefly luciferase (Fluc); the first catalytic half-reaction involves the adenylation of D-luciferin (LH₂), which produces the reaction intermediate, luciferyl adenylate (LH₂-AMP), while the second half-reaction involves the oxidation of LH₂-AMP, which produces oxyluciferin (OxL). Subsequently, the excited OxL emits light (**Figure 1A**) (Branchini et al., 2011; Sundlov et al., 2012). Two Fluc mutants named Donor and Acceptor were made of Fluc from *Photinus pyralis* (Ppy). The Donor maintains the activity in the first half-reaction but is defective in the second half-reaction, while the Acceptor has a low activity in the first half-reaction but mostly retains the activity in the second-half reaction.



Therefore, the Donor can produce the reaction intermediate, LH₂-AMP, while producing almost no OxL. However, the Acceptor cannot produce LH₂-AMP but can retain the catalytic activity for the oxidation of the intermediate. When the Donor and Acceptor are each fused to an interacting protein, the interaction of the proteins induces the approximation of the two mutant enzymes. Based on this principle, previously, we succeeded to detect 1) the interaction between FK506-binding protein 12 (FKBP12) and FKBP-rapamycin-associated protein (FRB), which interact depending on an immunosuppressant

rapamycin, and 2) that between p53 and its inhibitor Mdm2, which controls apoptosis, senescence, DNA repair and cell growth. Each PPI results in a higher rate of LH₂-AMP catalysis into OxL by the Acceptor, leading to the higher light emission (**Figure 1B**). This PPI assay was named Firefly luminescent intermediate Protein-protein Interaction Assay or FlimPia (Ohmuro-Matsuyama et al., 2013b; Ohmuro-Matsuyama et al., 2014; Kurihara et al., 2016; Ohmuro-Matsuyama and Ueda, 2016, 2017; Ohmuro-Matsuyama et al., 2018a; Ohmuro-Matsuyama et al., 2018b).

FlimPia has several advantages. The signal/background ratio and sensitivity are higher, and the detectable size of the interacting protein is larger than that of fluorescent protein-based Förster/fluorescence resonance energy transfer assay and Fluc-based protein-fragment complementation assay. Furthermore, the thermostability of the probe is 4-fold higher than that of Fluc PCA probes because of the unstable split forms of PCA probes and the structural integrity of FlimPia probes employing the full-length Fluc (Ohmuro-Matsuyama et al., 2013a).

However, the thermostability of FlimPia remains insufficient owing to the low stability of Ppy. Although Fluc is applied to a hygiene monitoring system (Corbitt et al., 2000; Bakke and Suzuki, 2018), incubation of the enzyme for 1 h at 37°C resulted in an 83% decrease in signal intensity. To overcome this problem, many researchers have attempted to enhance the stability of Fluc (White et al., 1996; Koksharov and Ugarova, 2011a; Koksharov and Ugarova, 2011b; Rasouli et al., 2011; Lohrasbi-Nejad et al., 2016; Solgi et al., 2016; Branchini and Southworth, 2017; Jazayeri et al., 2017; Rahban et al., 2017; Pozzo et al., 2018; Branchini et al., 2019). In this study, we applied *Luciola lateralis* (Heike-botaru) Fluc (LIL) with mutations for thermostability and organic solvent tolerance (Kodama and Nasu, 2011) to FlimPia for improving the stability at physiological reaction condition. LIL was obtained by random mutagenesis and screening of a high activity mutant L344A, encoding two mutations V287A and V392I.

2 MATERIALS AND METHODS

2.1 Materials

Firefly luciferin (LH₂) was obtained from Biosynth AG (Staad, Switzerland). Rapamycin was purchased from LKT Laboratories (St. Paul, MN, United States), and 3-(N-morpholino) propanesulfonic acid (MOPS) was purchased from Dojindo (Kumamoto, Japan). Oligonucleotides were synthesized by Eurofins (Tokyo, Japan). A QuikChange Site-Directed Mutagenesis Kit was obtained from Agilent (Santa Clara, CA, United States). An In-Fusion HD Cloning Kit was purchased from Takara-Bio (Shiga, Japan). Restriction enzymes and *E. coli* SHuffle T7 express lysY were obtained from New England Biolabs (Ipswich, MA, United States). *E. coli* JM109 competent cells were from SciTrove (Tokyo, Japan). Overnight Express Autoinduction System and BugBuster Master Mix were obtained from MERCK (Kenilworth, NJ, United States). Other reagents of the highest grade available were purchased from Kanto Chemicals (Tokyo,

Japan), Fujifilm-Wako Pure Chemical Industries (Osaka, Japan), or Nacalai-Tesque (Kyoto, Japan), unless otherwise indicated.

2.2 Construction of Plasmids and Their Libraries

The primers used in this study are listed in **Supplementary Table S1**. To yield pET26-LIL (H245D), QuikChange Site-Directed Mutagenesis Kit was used according to the manufacturer's protocol using pET26-LIL (Kodama and Nasu, 2011) as a template and the primer set of LILH245S_BspHI+ and LILH245D_BspHI+-r. To yield pET26-LIL(K443A), the same procedure was used with the primers of LILK443A_AseI+ and LILK443A_AseI+-r. To yield pET-LIL (K529A; the lysine was at 529 in Ppy and 530 in LIL), the primers of LILK530A_MfeI+ and LILK530A_MfeI+-r were used, whereas primers of LIL K530Q_AgeI+ and LILK530Q_AgeI+-r were used to yield pET26-LIL(K529Q).

To yield FK506-binding protein 12 (FKBP12)-fused LIL(K443A), LIL(K443A) was amplified by polymerase chain reaction (PCR) using pET26-LIL(K443A) as a template and the primers LILNotG4S-for and LILXho-rev. The amplified fragment was digested with *NotI* and *XhoI* and inserted between the *NotI* and *XhoI* sites of pET32-FKBP-Donor, which was constructed previously (Ohmuro-Matsuyama et al., 2013b). To yield FKBP12-rapamycin complex-associated protein (FRB)-fused LIL (K529Q), LIL (K529Q) was amplified by PCR using pET26-LIL(K529Q) as a template and the primers LILNotG4S-for and LILXho-rev. The amplified fragment was digested with *NotI* and *XhoI* and inserted between the same sites of pET32-FRB-Donor.

To acquire the FRB-LIL(S440X/K529Q) library, QuikChange site-directed mutagenesis was performed using pET32-FRB-LIL(K529Q) as a template and LIL447_KpnI and LILS440X-KpnI-r as primers. Because bulky amino acids such as leucine and phenylalanine at the position of 440 were suitable as the Ppy Acceptor, the primer LILS440X-KpnI-r was designed to selectively encode these residues at this position. To yield the FRB-LIL(S440M/K529X) library, the full-length pET32-FRB-LIL (S440M/K529Q) was amplified and site-directly mutated via PCR using the primer set of LIL530X-for and LILS530X-rev. As the primers encoded 15 nt each of homologous sequences at the ends, both ends of the amplified fragment were recombined by In-Fusion cloning. To yield the FKBP-LIL(H245X/K443A) library, the full-length pET32-FKBP-LIL(K443A) was amplified and site-directly mutated via PCR with the primer set of LILH245X-for and LILH245X-rev. Both ends of the amplified fragment were recombined using In-Fusion cloning. To obtain the FKBP-LILH245E/K443A library, pET32-FKBP-LIL(H245E/K443A) was amplified and site-directly mutated via PCR using the primer set of LILK443X-for and LILK443X-rev. Both ends of the amplified fragment were recombined using In-Fusion cloning, according to the manufacturer's protocol. To confirm that each resultant library contained sufficient variation of the mutants, the DNA sequences of several clones were analyzed.

To obtain FRB-LIL(S440F/K529Q) and FRB-LIL(S440W/K529Q), pET32-FRB-LIL (S440M/K529M) was amplified and

site-directly mutated by PCR using the primers LILS440FW-KpnI and LIL447-KpnI-r, and both ends of the amplified fragment were fused by In-Fusion cloning. pET32-FKBP-LIL(H245E/K443A/I530R) and pET32-FKBP-LIL(H245E/K443A/I530K) were obtained similarly using pET32-FKBP-LIL(H245E/K443A) as a template and LILI530X-for and LILI530X-rev as primers.

2.3 Expression and Characterization of the Probe Proteins

The probes for FlimPIA were expressed in *E. coli* SHuffle T7 Express lysY and purified using the TALON metal affinity resin, as described previously (Ohmuro-Matsuyama et al., 2013b). The purification profile of each protein was confirmed by SDS-PAGE (**Supplementary Figure S1**). The kinetic constants K_m and V_{max} for LH₂-AMP were determined using chemically synthesized LH₂-AMP, as described previously (Kurihara et al., 2016). To estimate the adenylation activity, the amount of enzymatically formed LH₂-AMP was measured using the N-domain of Ppy Fluc, as described previously (Ayabe et al., 2005).

2.4 Detection of PPI by FlimPIA

An equimolar mixture of the Donor and Acceptor candidates with or without rapamycin in the reaction buffer (50 μ l of 100 mM MOPS and 10 mM MgSO₄; pH 7.3), wherein the concentration of MgSO₄ and pH were previously optimized for FlimPIA (Ohmuro-Matsuyama et al., 2013b), was added to a well of a 96-well half-area white plate (3693, Corning, Tokyo, Japan). The measurement was performed using a microplate-based luminometer AB2350 at 0.1-s intervals (ATTO, Tokyo, Japan) immediately after injecting 50 μ l of the reaction buffer containing the substrates (LH₂ and ATP). Rapamycin was dissolved in dimethyl sulfoxide (DMSO), and the same amount of DMSO (0.1%) was added as a vehicle to the negative sample. In the optimized buffer conditions, 1 mM of coenzyme A was added to reduce the amount of spontaneously produced dehydroluciferyl-AMP (L-AMP), which acts as a competitor of LH₂-AMP and inhibits light emission. The addition of coenzyme A results in the conversion of L-AMP to dehydroluciferyl-coenzyme A, which does not act as a competitor (Fontes et al., 1997; Fraga et al., 2005; Kurihara et al., 2016).

2.5 Screening

E. coli SHuffle T7 Express lys Y was transformed with the mutant plasmids and cultured on LBA agar plates (10 g/L tryptone, 5 g/L yeast extract, 5 g/L sodium chloride, 100 μ g/ml ampicillin, and 15 g/L agar). The colonies were selected and cultured using the Overnight Express Autoinduction System in a 96-well culture plate at 30°C overnight. The pellet of each clone was lysed in 50 μ l of BugBuster Master Mix, according to the manufacturer's protocol. The lysates were centrifuged, and the supernatants were collected. To estimate the adenylation activity, each supernatant (10 μ l) was added to 90 μ l of reaction buffer containing 150 μ M of LH₂ and 2 mM ATP. To estimate the oxidative luminescent activity, 90 μ l of the reaction buffer containing 200 nM LH₂-AMP was added to each supernatant (10 μ l).

3 RESULTS AND DISCUSSION

3.1 Testing Ppy Mutations in LIL-Based FlimPIA

Previously, two mutant Ppy enzymes were used to perform FlimPIA. Fluc consists of N- and C-terminal domains, and the C-terminal domain rotates $\sim 140^\circ$ according to the reaction proceeds from the first to the second half-reaction (Branchini et al., 2011; Sundlov et al., 2012). Based on this knowledge, the H245D/K443A/I530R mutant of Ppy has been used as the Donor that produces luciferyl adenylate (Ohmuro-Matsuyama et al., 2013b). Among the three mutations, two mutations, H245D near the active site (Ayabe et al., 2005) and K443A in the C-terminal domain (Branchini et al., 2005), suppress the oxidative reaction steps, thereby playing a central role as the Donor. In contrast, being K529 as an essential residue for the adenylation reaction (Branchini et al., 2000), Ppy enzymes with the mutations K529A, K529Q, K529Q/S440F, or K529Q/S440W were used as the Acceptors. While the mutations at K529 are most important for the Acceptor that suppress the adenylation reaction, those for S440 located in the hinge region between the N- and C-terminal domains augment the steric hindrance to suppress the adenylation conformation (Ohmuro-Matsuyama et al., 2018b) (Figure 1). Based on these previous observations, we first obtained the LIL mutants of H245D, K443A, K529A, and K529Q and then analyzed their kinetic constants for LH₂-AMP (Supplementary Table S2). As a result, suppression of the oxidative reaction steps by H245D and K443A mutations was observed. In contrast, the reaction rate was relatively maintained by the K529A and K529Q mutant LILs. Next, the relative amounts of LH₂-AMP produced by the same mutant LILs were compared to analyze the adenylation activity. The amount of adenylate produced by K443A was higher than that produced by H245D, K529A, and K529Q (Supplementary Figure S2). These results indicate that K443A might act as a Donor because of its high adenylation activity and low oxidative activity, suggesting the importance of K443 in the oxidative steps in LIL. However, the adenylation activity of H245D was too low to act as a Donor. Next, FlimPIA using heterogeneous pairs of LIL-based and Ppy-based mutants was performed using 1) the pair of FKBP-fused LIL (K443A) as a Donor and FRB-fused Ppy Acceptor and 2) the pair of FKBP-fused Ppy Donor and FRB-fused LIL(K529Q) as a possible Acceptor (Supplementary Figure S3). Since the interaction between FKBP and FRB is rapamycin (Rap) dependent (Brown et al., 1994; Chiu et al., 1994; Chen et al., 1995), the luminescence intensity was expected to increase with the addition of Rap. As a result, when rapamycin was added to the first pair of LIL(K443A) and Ppy Acceptor, a higher luminescent intensity was observed in the presence of Rap. However, the second pair of LIL K529Q and Ppy Donor did not show a Rap-dependent signal.

3.2 Strategy for Screening LIL Mutants

Because the mutations of H245D and K529Q were not functional for LIL-based FlimPIA, we decided to perform screening for more suitable mutants by the following procedure. 1) The saturation mutagenesis libraries, K529X, S440X, H245X, and K443X were

screened. *E. coli* was transformed using the library, and several clones were expressed in the cultured *E. coli* using an autoinduction system. 2) To analyze the first half reaction, ATP and LH₂ were added to the lysates of *E. coli*. 3) To assess the second half reaction, LH₂-AMP was added to the lysates. 4) The ratios of the luminescence intensity of 2) and that of 3) were calculated. When the ratio was high, the clone was suitable as a Donor, whereas when the ratio was low, the clone was suitable as an Acceptor.

3.3 Screening for LIL Acceptor

As the interacting proteins, FKBP and FRB were used, and the rapamycin dependent interaction was detected (Figure 1B). To obtain an LIL-based Acceptor, an FRB/S440X/K529Q library was created, and 96 colonies were selected for screening. Among them, five clones, namely, FRB/S440N/K529Q (two clones), FRB/S440K/K529Q (two clones), and FRB/S440M/K529Q, were selected. The proteins of FRB/S440S/K529Q, FRB/S440N/K529Q, FRB/S440K/K529Q, and FRB/S440M/K529Q were expressed in *E. coli* and purified. Using each protein as the Acceptor and FKBP/Ppy Donor, FlimPIA was performed (Figure 2A). The luminescence intensities of all Acceptor candidates were increased by the addition of Rap. The maximum signal/background (S/B) ratios were in the order of S440M>S440K>S440N>S440S.

In our previous study (Ohmuro-Matsuyama and Ueda, 2017), Ppy (S440F/K529Q) and Ppy (S440W/K529Q) were found to be suitable as the Acceptors. To validate the results of the screening in this study, FRB/LIL(S440F/K529Q) and FRB/LIL(S440W/K529Q) were also prepared and tested. FlimPIA was performed using each FRB/LIL Acceptor candidate and FKBP/Ppy Donor. When Rap was added, the maximum S/B ratios of S440F/K529Q and S440W/K529Q were lower than those of S440S/K529Q (Supplementary Figure S4). Previously, we showed that the optimization of ATP concentration was important for the suppression of the background luminescence intensity and the enhancement of the S/B ratio. Although different concentrations of ATP (20, 5, and 1.25 mM) were examined, the maximum S/B ratios remained low. Therefore, we concluded that the screening method was suitable for the selection of mutants for FlimPIA.

To obtain a better mutant Acceptor, the FRB/LIL S440M/K529X library was constructed. In addition, 6 out of 192 clones were selected. The truncated Flucs were observed in two clones, and the remaining clones were FRB/S440M/K529R (two clones), FRB/S440M/K529M, and FRB/S440M/K529N. FlimPIA was performed using each FRB/LIL Acceptor candidate and FKBP/Ppy Donor. As a result, all candidates acted as the Acceptors, and the maximum S/B ratio of K529M was remarkably higher than that of the other candidates (Figure 2B).

3.4 Screening for LIL Donor

To obtain an LIL-based Donor, screening was performed using the FKBP/LIL H245X/K443A library. As a result, 9 out of 288 clones were selected. These included FKBP/H245N/K443A (three clones), FKBP/H245E/K443A (three clones), FKBP/H245A/K443A, FKBP/H245S/K443A, and FKBP/H245P/K443A.






FIGURE 2 | Screening of LIL Acceptors. **(A)** S440X/K529Q screening. **(B)** S440M/K529X screening. Error bar: $\pm 1 \times SD$ ($n = 3$). Ppy Donor (50 nM) and each candidate of LIL Acceptor (50 nM) were reacted with ATP (10 mM) and LH_2 (37.5 μM) with/without rapamycin (Rap) (50 nM).



FlimPIA was performed using each candidate and FRB/LIL(S440M/K529M). Among these candidates, only H245E/K443A showed increased luminescence intensity upon Rap addition (**Supplementary Figure S5**). However, the S/B ratio and luminescence intensity were significantly lower than those obtained with the FKBP/Ppy Donor and FRB/LIL(S440M/K529M).

To improve the LIL Donor, another screening was performed using the FKBP/LIL (H245E/K443X) library. Among 288 clones, H245E/K443R (three clones), H245E/K443G (two clones), H245E/K443V, H245E/K443P, and H245E/K443A were selected. FlimPIA was performed using each candidate and the FRB/Ppy Acceptor (K529Q/S440F) (**Supplementary Figure S6A**). However, the results using these candidates were almost the same for several ATP concentrations. In addition, FRB/LIL (H245E/K443A/I530R) and FRB/LIL (H245E/K443A/I530K)

were expressed in *E. coli* and purified. Because I530R is effective for the stabilization of ATP in Ppy (Fujii et al., 2007), we hypothesized that the positively charged amino acids at this position (I530R, I530K) might enhance the adenylation activity. However, in FlimPIA, these mutations decreased the luminescence intensities and could not increase the S/B ratios under several ATP concentrations (**Supplementary Figure S6B**).

3.5 FlimPIA Using Selected Enzymes

Because of the low intensity and S/B ratio of the FKBP/LIL Donor (H245E/K443A) and FRB/LIL Acceptor (S440M/K529M), the stability of the heterologous pair of the Ppy Donor and LIL Acceptor was compared with that of the LIL Donor and LIL Acceptor pair (**Supplementary Figure S7**). FlimPIA was performed after two overnight incubations at 25°C. Unexpectedly, the S/B ratio and luminescence intensity of the

heterologous pair were as high as those of the homologous pair. Ppy Donor might have produced an excess amount of LH₂-AMP for FlimPIA; therefore, the lower production of LH₂-AMP after the incubation might not remarkably change the result of FlimPIA.

We then selected the heterologous pair of FKBP/Ppy Donor and FRB/LIL Acceptor and optimized the assay conditions. Under the conditions of 1.25 mM ATP, 33 μM LH₂, and 1 mM coenzyme A, the maximum S/B ratio reached more than 6 (Figure 3A). In addition, when a portable luminometer (Lumitester PD-30, Kikkoman, Chiba, Japan) was used, an S/B ratio of more than 2 was attained (Figure 3B). Finally, we compared the thermostabilities of the Ppy pair of FKBP/Ppy Donor and FRB/Ppy Acceptor and the heterologous pair of FKBP/Ppy Donor and FRB/LIL Acceptor at 37°C (Figure 4). After incubation for 20 and 60 min, the signal intensity of the Ppy pair was 58 and 17%, while the intensity of the heterologous pair was still 72 and 41%, respectively.

In conclusion, we succeeded in improving the thermostability of FlimPIA, enhancing its applicability for clinical diagnoses and inspections in such as food factories. In this study, it was revealed that both Ppy Fluc and LIL Fluc could be applied to FlimPIA. In the future, other similar enzymes such as Eluc (enhanced green-emitting luciferase) (Nakajima et al., 2010), which produces a brighter light in mammalian cells, may further expand the scope of this assay in practical applications.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

REFERENCES

- Amiri Dash Atan, N., Koushki, M., Rezaei Tavirani, M., and Ahmadi, N. A. (2018). Protein-Protein Interaction Network Analysis of Salivary Proteomic Data in Oral Cancer Cases. *Asian Pac. J. Cancer Prev.* 19 (6), 1639–1645. doi:10.22034/APJCP.2018.19.6.1639
- Ashkenazi, S., Plotnikov, A., Bahat, A., and Dikstein, R. (2017). Effective Cell-free Drug Screening Protocol for Protein-Protein Interaction. *Anal. Biochem.* 532, 53–59. doi:10.1016/j.ab.2017.05.030
- Ayabe, K., Zako, T., and Ueda, H. (2005). The Role of Firefly Luciferase C-Terminal Domain in Efficient Coupling of Adenylation and Oxidative Steps. *FEBS Lett.* 579 (20), 4389–4394. doi:10.1016/j.febslet.2005.07.004
- Bakke, M., and Suzuki, S. (2018). Development of a Novel Hygiene Monitoring System Based on the Detection of Total Adenylate (ATP+ADP+AMP). *J. Food Prot.* 81 (5), 729–737. doi:10.4315/0362-028X.JFP-17-432
- Branchini, B. R., Fontaine, D. M., Southworth, T. L., Huta, B. P., Racela, A., Patel, K. D., et al. (2019). Mutagenesis and Structural Studies Reveal the Basis for the Activity and Stability Properties that Distinguish the Photinus Luciferases Scintillans and Pyralis. *Biochemistry* 58 (42), 4293–4303. doi:10.1021/acs.biochem.9b00719
- Branchini, B. R., Murtiashaw, M. H., Magyar, R. A., and Anderson, S. M. (2000). The Role of Lysine 529, a Conserved Residue of the Acyl-Adenylate-Forming Enzyme Superfamily, in Firefly Luciferase. *Biochemistry* 39 (18), 5433–5440. doi:10.1021/bi9928804
- Branchini, B. R., Rosenberg, J. C., Fontaine, D. M., Southworth, T. L., Behney, C. E., and Uzasci, L. (2011). Bioluminescence Is Produced from a Trapped Firefly Luciferase Conformation Predicted by the Domain Alternation Mechanism. *J. Am. Chem. Soc.* 133 (29), 11088–11091. doi:10.1021/ja2041496
- Branchini, B. R., and Southworth, T. L. (2017). A Highly Sensitive Biosensor for ATP Using a Chimeric Firefly Luciferase. *Methods Enzymol.* 589, 351–364. doi:10.1016/bs.mie.2017.01.004
- Branchini, B. R., Southworth, T. L., Murtiashaw, M. H., Wilkinson, S. R., Khattak, N. F., Rosenberg, J. C., et al. (2005). Mutagenesis Evidence that the Partial Reactions of Firefly Bioluminescence Are Catalyzed by Different Conformations of the Luciferase C-Terminal Domain. *Biochemistry* 44 (5), 1385–1393. doi:10.1021/bi047903f
- Brown, E. J., Albers, M. W., Bum Shin, T., Ichikawa, K., Keith, C. T., Lane, W. S., et al. (1994). A Mammalian Protein Targeted by G1-Arresting Rapamycin-Receptor Complex. *Nature* 369 (6483), 756–758. doi:10.1038/369756a0
- Chen, J., Zheng, X. F., Brown, E. J., and Schreiber, S. L. (1995). Identification of an 11-kDa FKBP12-Rapamycin-Binding Domain within the 289-kDa FKBP12-Rapamycin-Associated Protein and Characterization of a Critical Serine Residue. *Proc. Natl. Acad. Sci.* 92 (11), 4947–4951. doi:10.1073/pnas.92.11.4947
- Chiu, M. I., Katz, H., and Berlin, V. (1994). RAPT1, a Mammalian Homolog of Yeast Tor, Interacts with the FKBP12/rapamycin Complex. *Proc. Natl. Acad. Sci.* 91 (26), 12574–12578. doi:10.1073/pnas.91.26.12574
- Corbitt, A. J., Bennion, N., and Forsythe, S. J. (2000). Adenylate Kinase Amplification of ATP Bioluminescence for hygiene Monitoring in the Food and Beverage Industry. *Letts. Appl. Microbiol.* 30 (6), 443–447. doi:10.1046/j.1472-765x.2000.00744.x
- Fontes, R., Dukhovich, A., Sillero, A., and Sillero, M. A. G. (1997). Synthesis of Dehydroluciferin by Firefly Luciferase: Effect of Dehydroluciferin, Coenzyme A and Nucleoside Triphosphates on the Luminescent Reaction. *Biochem. Biophysical Res. Commun.* 237 (2), 445–450. doi:10.1006/bbrc.1997.7161
- Fraga, H., Fernandes, D., Fontes, R., and Esteves da Silva, J. C. G. (2005). Coenzyme A Affects Firefly Luciferase Luminescence Because it Acts as a Substrate and

AUTHOR CONTRIBUTIONS

YO-M designed and carried out the experiments and wrote the manuscript draft. TS performed the experiments under the guidance of YO-M and HY. HU conceived the study and wrote the manuscript with the inputs from all authors. KG supplied the LIL gene and supported the experiments. HY provided research facility and funding. All authors have given approval to the final version of the manuscript.

FUNDING

This work was supported in part by JSPS KAKENHI Grant Numbers JP18H03851 (to HU), and JP17K06920 (to YO-M) from the Japan Society for the Promotion of Science, Japan.

ACKNOWLEDGMENTS

We thank Chiaki Toyama for experimental help, the Biomaterials Analysis Division, Open Facility Center, Tokyo Institute of Technology for DNA sequence analysis, and the support by Dynamic Alliance for Open Innovation Bridging Human, Environment and Materials from MEXT, Japan.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fbioe.2021.778120/full#supplementary-material>

- Not as an Allosteric Effector. *FEBS J.* 272 (20), 5206–5216. doi:10.1111/j.1742-4658.2005.04895.x
- Fujii, H., Noda, K., Asami, Y., Kuroda, A., Sakata, M., and Tokida, A. (2007). Increase in Bioluminescence Intensity of Firefly Luciferase Using Genetic Modification. *Anal. Biochem.* 366 (2), 131–136. doi:10.1016/j.ab.2007.04.018
- Gul, S., and Hadian, K. (2014). Protein-protein Interaction Modulator Drug Discovery: Past Efforts and Future Opportunities Using a Rich Source of Low- and High-Throughput Screening Assays. *Expert Opin. Drug Discov.* 9 (12), 1393–1404. doi:10.1517/17460441.2014.954544
- Jazayeri, F. S., Amininasab, M., and Hosseinkhani, S. (2017). Structural and Dynamical Insight into Thermally Induced Functional Inactivation of Firefly Luciferase. *PLoS One* 12 (7), e0180667. doi:10.1371/journal.pone.0180667
- Katam, R., Sakata, K., Suravajhala, P., Pechan, T., Kambiranda, D. M., Naik, K. S., et al. (2016). Comparative Leaf Proteomics of Drought-Tolerant and -susceptible Peanut in Response to Water Stress. *J. Proteomics* 143, 209–226. doi:10.1016/j.jprot.2016.05.031
- Kodama, Y., and Nasu, E. (2011). *Firefly Luciferase and Gene Thereof, and Process for Production of Firefly Luciferase*. PCT patent application. WO 2011/058767 A1, Geneva, Switzerland: World Intellectual Property Organization.
- Koksharov, M. I., and Ugarova, N. N. (2011a). Thermostabilization of Firefly Luciferase by *In Vivo* Directed Evolution. *Protein Eng. Des. Sel* 24 (11), 835–844. doi:10.1093/protein/gzr044
- Koksharov, M. I., and Ugarova, N. N. (2011b). Triple Substitution G216N/A217L/S398M Leads to the Active and Thermostable *Luciola Mingrelica* Firefly Luciferase. *Photochem. Photobiol. Sci.* 10 (6), 931–938. doi:10.1039/c0pp00318b
- Kurihara, M., Ohmuro-Matsuyama, Y., Ayabe, K., Yamashita, T., Yamaji, H., and Ueda, H. (2016). Ultra Sensitive Firefly Luciferase-based Protein-protein Interaction Assay (FlimPIA) Attained by Hinge Region Engineering and Optimized Reaction Conditions. *Biotechnol. J.* 11 (1), 91–99. doi:10.1002/biot.201500189
- Lohrasbi-Nejad, A., Torzadeh-Mahani, M., and Hosseinkhani, S. (2016). Hydrophobin-1 Promotes Thermostability of Firefly Luciferase. *FEBS J.* 283 (13), 2494–2507. doi:10.1111/febs.13757
- Nakajima, Y., Yamazaki, T., Nishii, S., Noguchi, T., Hoshino, H., Niwa, K., et al. (2010). Enhanced Beetle Luciferase for High-Resolution Bioluminescence Imaging. *PLoS One* 5 (4), e10011. doi:10.1371/journal.pone.0100111
- Ohmuro-Matsuyama, Y., Chung, C.-I., and Ueda, H. (2013a). Demonstration of Protein-Fragment Complementation Assay Using Purified Firefly Luciferase Fragments. *BMC Biotechnol.* 13, 31. doi:10.1186/1472-6750-13-31
- Ohmuro-Matsuyama, Y., Hara, Y., and Ueda, H. (2014). Improved Protein-Protein Interaction Assay FlimPIA by the Entrapment of Luciferase Conformation. *Anal. Chem.* 86 (4), 2013–2018. doi:10.1021/ac403065v
- Ohmuro-Matsuyama, Y., Nakano, K., Kimura, A., Ayabe, K., Ihara, M., Wada, T., et al. (2013b). A Protein-Protein Interaction Assay Based on the Functional Complementation of Mutant Firefly Luciferases. *Anal. Chem.* 85 (16), 7935–7940. doi:10.1021/ac4016825
- Ohmuro-Matsuyama, Y., and Ueda, H. (2016). A Protein-Protein Interaction Assay FlimPIA Based on the Functional Complementation of Mutant Firefly Luciferases. *Methods Mol. Biol.* 1461, 131–142. doi:10.1007/978-1-4939-3813-1_10
- Ohmuro-Matsuyama, Y., and Ueda, H. (2017). Ultrasensitive Firefly Luminescent Intermediate-Based Protein-Protein Interaction Assay (FlimPIA) Based on the Functional Complementation of Mutant Firefly Luciferases. *Methods Mol. Biol.* 1596, 119–130. doi:10.1007/978-1-4939-6940-1_8
- Ohmuro-Matsuyama, Y., Yamashita, T., Gomi, K., Yamaji, H., and Ueda, H. (2018a). Evaluation of Protein-Ligand Interactions Using the Luminescent Interaction Assay FlimPIA with Streptavidin-Biotin Linkage. *Anal. Biochem.* 563, 61–66. doi:10.1016/j.ab.2018.10.010
- Ohmuro-Matsuyama, Y., Yamashita, T., Lin, H., Yamaji, H., and Ueda, H. (2018b). Improved Sensitivity of Firefly Luminescent Intermediate-Based Protein Interaction Assay Using Ser 440 Mutant with Lower Adenylation Activity. *Luminescence* 33 (1), 125–130. doi:10.1002/bio.3381
- Pozzo, T., Akter, F., Nomura, Y., Louie, A. Y., and Yokobayashi, Y. (2018). Firefly Luciferase Mutant with Enhanced Activity and Thermostability. *ACS Omega* 3 (3), 2628–2633. doi:10.1021/acsomega.7b02068
- Rahban, M., Salehi, N., Saboury, A. A., Hosseinkhani, S., Karimi-Jafari, M. H., Firouzi, R., et al. (2017). Histidine Substitution in the Most Flexible Fragments of Firefly Luciferase Modifies its thermal Stability. *Arch. Biochem. Biophys.* 629, 8–18. doi:10.1016/j.abb.2017.07.003
- Rasooly, A. (2001). Surface Plasmon Resonance Analysis of Staphylococcal Enterotoxin B in Food. *J. Food Prot.* 64 (1), 37–43. doi:10.4315/0362-028x-64.1.37
- Rasouli, S., Hosseinkhani, S., Yaghmaei, P., and Ebrahim-Habibi, A. (2011). Effects of Sucrose and Trehalose on Stability, Kinetic Properties, and thermal Aggregation of Firefly Luciferase. *Appl. Biochem. Biotechnol.* 165 (2), 572–582. doi:10.1007/s12010-011-9276-1
- Solgi, Z., Khalifeh, K., Hosseinkhani, S., and Ranjbar, B. (2016). Surface Arginine Saturation Effect on Unfolding Reaction of Firefly Luciferase: A Thermodynamic and Kinetic Perspective. *Photochem. Photobiol.* 92 (5), 688–693. doi:10.1111/php.12614
- Sundlov, J. A., Fontaine, D. M., Southworth, T. L., Branchini, B. R., and Gulick, A. M. (2012). Crystal Structure of Firefly Luciferase in a Second Catalytic Conformation Supports a Domain Alternation Mechanism. *Biochemistry* 51 (33), 6493–6495. doi:10.1021/bi300934s
- White, P. J., Squirrell, D. J., Arnaud, P., Lowe, C. R., and Murray, J. A. H. (1996). Improved Thermostability of the North American Firefly Luciferase: Saturation Mutagenesis at Position 354. *Biochem. J.* 319 (Pt 2), 343–350. doi:10.1042/bj3190343
- Xu, M., Liu, C., Zhou, M., Li, Q., Wang, R., and Kang, J. (2016). Screening of Small-Molecule Inhibitors of Protein-Protein Interaction with Capillary Electrophoresis Frontal Analysis. *Anal. Chem.* 88 (16), 8050–8057. doi:10.1021/acs.analchem.6b01430
- Yuan, X., Chen, J., Lin, Y., Li, Y., Xu, L., Chen, L., et al. (2017). Network Biomarkers Constructed from Gene Expression and Protein-Protein Interaction Data for Accurate Prediction of Leukemia. *J. Cancer* 8 (2), 278–286. doi:10.7150/jca.17302

Conflict of Interest: Authors YO-M and KG are employed by Shimadzu Corporation and Kikkoman, Co., Ltd. respectively.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ohmuro-Matsuyama, Gomi, Shimoda, Yamaji and Ueda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.